SCHEMBL6867189

SCHEMBL6867189

C=CCOc1cc(=O)oc2c(C)c(O[C@@H]3OC(C)(C)[C@H](OC)[C@H](O)[C@H]3O)ccc12

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
HSP90AA1 P07900 7/20 0.50
HSP90AB1 P08238 7/20 0.50
MAP1LC3B Q9GZQ8 2/20 0.44
MAP1LC3A Q9H492 2/20 0.44
POLQ O75417 1/20 0.44
ALB P02768 1/20 0.44
KDR P35968 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
KMT2A Q03164 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6867185 1.00 KDM4E (0.51) KDM4EALDH1A1MAPTHPGDHSP90AA1
SCHEMBL6864405 0.85 KDM4E (0.42) KDM4EALDH1A1MAPTHPGDHSP90AA1
SCHEMBL6864406 0.85 KDM4E (0.42) KDM4EALDH1A1MAPTHPGDHSP90AA1
SCHEMBL8444987 0.81 HSP90AB1 (0.49) KDM4EHSP90AA1HSP90AB1MAP1LC3BMAP1LC3A
SCHEMBL6156108 0.81 HSP90AB1 (0.49) KDM4EHSP90AA1HSP90AB1MAP1LC3BMAP1LC3A
SCHEMBL6867028 0.81 HSP90AB1 (0.51) KDM4EALDH1A1HPGDHSP90AA1HSP90AB1
SCHEMBL6866195 0.81 HSP90AB1 (0.52) KDM4EALDH1A1HPGDHSP90AA1HSP90AB1
SCHEMBL6867022 0.81 HSP90AB1 (0.51) KDM4EALDH1A1HPGDHSP90AA1HSP90AB1
SCHEMBL6866197 0.81 HSP90AB1 (0.52) KDM4EALDH1A1HPGDHSP90AA1HSP90AB1
SCHEMBL6938071 0.80 HSP90AB1 (0.46) KDM4EALDH1A1MAPTHPGDHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812331-B2 BACTERICIDES AVENTIS PHARMA S.A. (FR) 2004-11-02 US disclosed
US-6350733-B1 4-HYDROXYBENZOPYRAN-2-ONE DERIVATIVES; BACTERICIDES FOR STAPHYLOCOCCUS INFECTIONS; SKIN DISORDERS AVENTIS PHARMA S.A. (FR) 2002-02-26 US disclosed
US-20020010322-A1 New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments AVENTIS PHARMA S.A. 2002-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010322-A1 New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments RPIA, CD38, PARP1 KDM4E 1566/4885ALDH1A1 1370/4885MAPT 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.